The Story of Expanding Reach: Millions of Patients, One Question Away
A student once asked how to approach repurposing established medicines for new needs. They expected a methodology, perhaps a reading list. The honest answer was neither. It was a single conversation.
A senior endocrinologist mentioned, almost in passing, that they routinely used an established medicine for itch management in patients living with diabetes. It was said the way clinicians say many things: casually, from experience, without any sense that it was remarkable. That casual observation deserved a closer look. What followed reached millions.
The hidden burden. Published estimates suggest nearly half of all people living with type 2 diabetes experience itching. For a significant minority, it is severe enough to disturb sleep, affect daily life, and need treatment. Across a country with tens of millions of people living with diabetes, that is millions of patients, suffering quietly with a problem almost nobody was treating.
Why was nobody addressing it? Not because the medicine did not exist. It existed, it was proven, and it was affordable. The failure was a three-way awareness gap. Patients did not think itch was worth mentioning in a diabetes consultation; they had learned that these appointments were about sugar readings. Caregivers did not connect itching to diabetes at all. And physicians were rightly focused on glucose control and the complications that threaten life and organ function: heart, kidney, nerve, and eye. Nobody was at fault. Everybody was missing it. The medicine was available. The patients were waiting. The bridge was simply missing.
What bridged it was discipline, not complexity. The answer was not a new study or a new molecule. It was a collaborative educational program that brought endocrinologists, physicians, and dermatologists into the same conversation, so that a symptom sitting between three specialties finally had owners in all of them. And it was one screening question, added to routine diabetes consultations: “Is itching affecting your sleep or daily life?”
Six words. That question unlocked access for millions. Patients who had normalised their suffering were identified in ordinary appointments. Quality of life improved, with a proven, affordable, already-available medicine. And business outcomes followed, as they reliably do when patient access comes first.
The lesson for every mature product. The strategic question is rarely “what new molecule do we need?” It is “has this medicine truly reached every patient who can benefit from it?” Most mature products are surrounded by patients nobody has looked for: populations hidden behind unasked questions, unconnected specialties, and symptoms everyone has learned to walk past.
Sometimes the most impactful strategy is not discovering something new. It is ensuring what already works finally reaches who it was always meant to serve. The only remaining question is the one worth ending on: what simple clinical observation in your world are you walking past every day?
Key message boxes:
- Studies suggest nearly half of people with type 2 diabetes experience itch. Most never mention it.
- One screening question, six words, unlocked access for millions.
- Mature product growth rarely needs new science. It needs the right conversation, systematically asked.
This article is based on real professional experience, shared as a learning for educational purposes. Product, company, and clinical details are anonymized and simplified. Nothing herein constitutes medical advice or the promotion of any specific product.